Lake lowering in sulphide-rich areas is currently a major environmental impact for surface water. This study focuses on whether there is a relationship between a gradient of lake lowering and surface water impacts in areas of sulphide-rich sediments, in order to better understand their contribution of heavy metals and sulfuric acid. Also, is it a reasonable method to use the reduced lake area in order to quantify the gradient? The survey was conducted by collecting water samples from reference lakes and lowered lakes from south to north in coastal areas within the county of Västerbotten. Water samples were then analyzed for TOC, pH, conductivity, anions, base cations, alkalinity, acidity, sulfate, Al, Cd, Fe, Mn, Cu, Zn and Pb. These parameters were then compared statistically using regression analysis and t-tests. The results show that no gradient was discernible in response to the reduced lake area. However, significant differences (p < 0,05) between the reference lakes and all the reduced lakes were visible for pH, conductivity, Cd, Cu, Zn and Al. The study shows that there is a correlation between lake lowering and negative impacts on surface water. However, to calculate a gradient from the reduced lake area is deficient as it is limited by the lakes volume reduction, and how the area around the lake has been affected. Further studies on the subject are therefore necessary. / FLISIK (för livskraftiga småvatten i kvarkenregionen)

The advent of the 4th generation X-ray sources paves the way for a new phase of experimental investigation of Hot-Dense plasmas. At the Linac Coherent Light Source (LCLS), pulses of keV X-rays, shorter than 100 fs, and with intensities up to 10¹⁸ W·cm^-2, are routinely produced, allowing for the production of uniform samples of solid-density plasmas. The simple single-photon X-ray absorption mechanism can be easily modelled, so that the plasma conditions can be accurately retrieved, without relying on diagnostic techniques that are not benchmarked in this high density regime. The work presented here describes the results of the first experiment where the LCLS interacts with a solid Al target, isochorically heating it at temperatures up to 190 eV. The system is described by the SCFLY non-LTE model, where the density and temperature are computed self consistently, as a consequence of the detailed atomic processes, rather than imposed by the user. The approximations affecting the simulations are discussed in detail. The code is first validated, by modelling the charge state distribution measured in a previous experiment (L. Young et. al), where the LCLS interacts with a Ne gas, a simplified (collisionless) problem. Then it is used to model the K-alpha spectroscopic data obtained for Al. The plasma evolution, explained by SCFLY simulations, is found to be primarily determined by collisions, whose visible effects on the experimental spectra are discussed. By varying the wavelength of the laser and observing the change in the K-alpha fluorescence, the K-edges for different ions in the plasma were determined, leading to a charge resolved measurement of continuum lowering in the HDM system. The results disagree with the widely used Stewart-Pyatt model, with the disagreement increasing for higher charge states, but are consistent with the older Ecker-Kroell model. These results have profound implications for dense plasma modelling.

Background: Clinical management of dyslipidemia is challenging, particularly hypertriglyceridemia in patients with HIV-infection. Changing combined anti-retroviral therapy (CART) and the use of lipid-lowering drugs have proven useful in treating dyslipidemia in HIV infected patients Objective: To assess the efficacy of lipid lowering drugs (LLDs) and/or CART switching, in the management of HIV-associated dyslipidemia Design: A retrospective, longitudinal cohort study Setting: Phidisa HIV research project, 6 sites in South Africa, period April 2008 and April 2011 Patients: HIV positive South African National Defence Force (SANDF) members and their dependents; who are on CART and are 18 years or older. Four hundred and forty eight participants with dyslipidemia had non-fasted, total serum cholesterol ≥ 8.0mmol/l, serum triglyceride levels ≥4.52 mmol/l and naïve to lipid lowering drugs at baseline. Measurements: Mean change over time of total serum cholesterol and serum triglyceride in the following treatment strategies were used: exercise and dietary advice, lipid-lowering drugs (statins or fibrates or both), CART switches separately and combined lipid lowering drug with ART switch was measured using panel data with first–order autoregressive-response and xtabond. Results: The mean age for a total of 448 participants was 39.9 years; males were 87%, females were only 13%. The participants contributed to 1861 follow-up visits. CD4 count was normally distributed with the baseline mean value of 402 cells/mm3 (18.5%). Mean change over time for total serum cholesterol and triglycerides increased by 0.099 mmol/l (p=0.007) and 0.248 mmol/l (p=0.018) respectively, with an increase in body mass index while an increase in CD4 cell percent decreased mean over time for total serum cholesterol by 0.045 mmol/l (p=0.002). Our hypothesis was confirmed when lipid lowering drugs and ART switch combined treatment strategy even more decrease in the mean total serum cholesterol and triglycerides levels over time by 0.754 mmol/l (p<0.001) and 2.073 mmol/l (p<0.001) respectively compared to the exercise and dietary advice treatment strategy. Our findings showed that combined treatment strategy maintained a decrease in both the mean total serum cholesterol and triglycerides levels over time of 0.283 mmol/l (p=0.038) and 0.941 mmol/l (p=0.016) respectively, when compared to lipid lowering drugs; the mean serum triglycerides over time were also reduced by 0.486 mmol/l (p=0.048) when the combined treatment strategy was compared to CART switch only. Furthermore combined treatment strategy of lipid lowering drugs with ART switch showed significant virological suppression by decreasing log of viral load, 0.486 (p<0.001) when compared to the exercise and dietary advice group. Conclusions: Combining lipid lowering drugs and ART switching as a treatment strategy in the management of HIV-associated dyslipidemia is effective in lowering the mean over time of both total serum cholesterol and triglycerides when compared to exercise and dietary advice strategy, while maintaining virological suppression. / Dissertation (MSc)--University of Pretoria, 2015. / tm2015 / School of Health Systems and Public Health (SHSPH) / MSc / Unrestricted

This thesis has investigated the effects of running the two full scale biogas digesters at Slottshagen wastewater treatment plant at 34 °C compared to 37 °C, in terms of process stability, biogas production and energy savings with the aim of saving energy and money by not heating the digesters as much. The main objective was to investigate whether it is at all possible to operate the biogas process at 34 °C or if the process becomes inhibited or otherwise unstable. If the process could be operated at 34 °C it might mean savings of both energy and money, provided that there is still a sufficient production of biogas.The experiment lasted for three months and investigated the short-term effects of the reduction of temperature. The process was monitored closely, and samples from the reactors were collected and analysed twice a week to ensure the stability of the biogas process. Several parameters were monitored online, the biogas production and methane content amongst others. Other parameters were calculated, such as the degree of degradation and specific methane production. This was done to ensure process stability and a sufficient production of biogas. The energy balance was calculated to evaluate if energy was saved by lowering the temperature in the digesters.The results show that the biogas process does remain stable at 34 °C while still producing a satisfactory amount of biogas during the short time of the experiment. Calculations show that both energy and money has been saved during the experiment. However, the system is largely dependent on seasonal variations, therefore further studies over a longer time period would be desirable. During the course of the thesis it has also become evident that the biogas process at Slottshagen is irregular in several aspects, and that it would be beneficial to even the process out, especially with regards to the hydraulic retention time. Making the process more even would enable further improvements to be made and simplify interpretations and comparisons of processstability data.

Fyodor Dostoevsky wrote in his acclaimed novel Crime and Punishment, "if he has a conscience he will suffer for his mistake. That will be punishment as well as the prison."1 The plague of guilt on the mind of a criminal is a key element in this book and is quite applicable to the case study at hand which examines why some juveniles are habitual criminal offenders. What prompts a youth to commit crimes? How does a child deal with his conscience for the unlawful acts? Does he understand right from wrong, truth from falsehoods, and freedom from repercussions? And should there be more stringent punishments by the state for committing the offenses? Society has developed ideas on what is acceptable in handling problem children. The justice system has turned from the idea of punishing offending youths to rehabilitating them. However, given the many problems our country faces with crime rates for juvenile offenders, perhaps society should question if the methods currently employed are effective. This examination specifically reviews the crime rates in Florida and how the law is applied to youths. This thesis aims to discover aspects of what encourages children to commit violent acts and which governmental and societal methods employed are successful or ineffective in treating this behavior. The purpose of this thesis is to probe the boundaries of our society and provoke social imagination to find resolutions in how the state may bring down crime rates for this age group.

京都大学 / 新制・課程博士 / 博士(医学) / 甲第25165号 / 医博第5051号 / 新制||医||1071(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 尾野 亘, 教授 西浦 博, 教授 佐藤 俊哉 / 学位規則第4条第1項該当 / Doctor of Agricultural Science / Kyoto University / DFAM

Leong Wai Ling Vivian. / Thesis submitted in: November 2004. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2005. / Includes bibliographical references (leaves 132-136). / Abstracts in English and Chinese. / Chapter Chapter One --- Introduction --- p.1-4 / Chapter Chapter Two --- Theoretical framework and literature review --- p.5-24 / Chapter Chapter Three --- Operationalization --- p.25-29 / Chapter Chapter Four --- Temporal staging of flag-raising ritual --- p.30-62 / Chapter Chapter Five --- Situational staging of flag-raising ritual --- p.63-120 / Chapter Chapter Six --- Conclusion --- p.121-131 / Bibliography

Thesis (MSc)--Stellenbosch University, 2013. / ENGLISH ABSTRACT: There is a global demand for technologies to reduce ethanol levels in wine without compromising wine quality. While several chemical and physical methods have been developed to reduce ethanol in finished wine, the target of an industrially applicable biological solution has thus far not been met. Most attempted biological strategies have focused on developing new strains of the main fermentative organism, the yeast Saccharomyces cerevisiae. Gene modification approaches have primarily focused on partially redirecting yeast carbon metabolism away from ethanol production towards glycerol production. These techniques have met with some moderate success, thus the focus of the current study was to re-direct carbon flux towards trehalose production by moderate over-expression of the TPS1 gene. This gene encodes trehalose-6-phosphate synthase, which converts glucose 6-phosphate and UDPglucose to α,α-trehalose 6-phosphate. Previous data have shown that the overproduction of trehalose restricts hexokinase activity reducing the amount of glucose that enters glycolysis. Nevertheless, preliminary TPS1 over-expression studies using multiple copy plasmids have shown some promise, but also indicated significant negative impact on the general fermentation behaviour of strains. In order to reduce such negative impacts of excessive trehalose production, a new strategy consisting in increasing the expression of TPS1 only during specific growth phases and by a relatively minor degree was investigated. Our study employed a lowcopy number episomal vector to drive moderate over-expression of the TPS1 gene in the widely used industrial strain VIN13 at different stages during fermentation. The fermentations were performed in synthetic must with sugar levels representative of those found in real grape must. This, as well as the use of an industrial yeast strain, makes it easier to relate our results to real winemaking conditions. A reduction in fermentation capacity was observed for all transformed strains and controls. Expression profiles suggest that the DUT1 promoter certainly results in increased TPS1 expression (up to 40%) during early exponential growth phase compared to the wild type strain (VIN13). TPS1 expression under the control of the GIP2 promoter region showed increased expression levels during early stationary phase (up to 60%). Chemical analysis of the yeast and the must at the end after fermentation showed an increase in trehalose production =in line with the expression data of TPS1. Importantly, glycerol production was also slightly increased, but without affecting acetic acid levels for the transformed strains. Although ethanol yield is not significantly lower in the DUT1-TPDS1 strain, s statistically significantly lower ethanol yield is observed for over-expression under the GIP2 promotor. Increasing trehalose production during stationary phase appears therefore to be a more promising approach at lowering ethanol yield and redirecting flux away from ethanol production. This controlled, growth phase specific over expression suggests a unique approach of lowering ethanol yield while not impacting on the redox balance. / AFRIKAANSE OPSOMMING: Wêreldwyd is daar ‘n aanvraag na tegnologie wat die etanol vlakke in wyn kan verminder sonder om wyngehalte te benadeel. Terwyl verskeie chemiese en fisiese metodes ontwikkel is om etanol in die finale wynproduk te verminder, is die soeke na 'n industrieel gebaseerde biologiese oplossing tot dusver nie gevind nie. Meeste biologiese strategieë fokus op die ontwikkeling van nuwe rasse van die primêre fermentatiewe organisme, naamlik Saccharomyces cerevisiae. Geen modifikasie benaderings het hoofsaaklik gefokus op die gedeeltelike kanalisering van koolstof metabolisme weg van etanol produksie na gliserol produksie. Hierdie benadering is net matiglik suksesvol, dus is ons huidige fokus om koolstof te kanaliseer na trehalose produksie deur gematigde oor-uitdrukking van die TPS1 geen. Hierdie geen kodeer vir trehalose-6-fosfaat sintase, wat glukose-6-fosfaat en UDP-glukose omskakel na α, α-trehalose-6-fosfaat. Vorige data het getoon dat die oorproduksie van trehalose hexokinase aktiwiteit beperk en die hoeveelheid glukose wat glikolise binne gaan. Voorlopige TPS1 ooruitdrukking studies met behulp van multi-kopie plasmiede toon matige sukses, maar het ook ‘n negatiewe impak op die algemene fermentasie kapasiteit van die gis. Ten einde so 'n negatiewe impak van oormatige trehalose produksie te oorkom, is 'n nuwe strategie gevolg wat bestaan uit die verhoogde uitdrukking van die TPS1 geen slegs gedurende spesifieke groei fases met baie lae vlakke van oor-uitdrukking. Ons studie gebruik 'n lae-kopie episomale vektor met matige oor-uitdrukking van die TPS1 geen in die industriële ras VIN13 op verskillende stadiums tydens fermentasie. Die fermentasie is uitgevoer in sintetiese mos met suiker vlakke verteenwoordigend van dié van werklike wyn mos. Hierdie, sowel as die gebruik van 'n industriële gisras, maak dit makliker om ons resultate te vergelyk met regte wyn fermentasie kondisies. Verlaagde fermentasie kapasiteit is waargeneem vir alle getransformeerde stamme en hul kontroles. Geen uitdrukkings profiele dui op verhoogde TPS1 uitdrukking (tot 40%) onder beheer van die DUT1 promotor gedurende die vroeë eksponensiële groeifase wanneer vergelyk word met die wilde tiepe (VIN13). TPS1 uitdrukking onder die beheer van die GIP2 promotor het verhoogde uitdrukking van tot 60% gedurende die vroeë stasionêre fase. Chemiese analise van die gis aan die einde van fermentasie dui op ‘n toename in trehalose produksie wat korreleer met die uitdrukking profiele van TPS1. Gliserol produksie is ook effens verhoog, maar sonder ‘n toename in asynsuur vlakke vir die getransformeerde rasse. Alhoewel etanol opbrengs nie aansienlik laer vir die DUT1-TPS1 ras is nie, is etanol opbrengs vir die oor-uitdrukking onder beheer van die GIP2 promotor wel laer. Toenemende trehalose produksie gedurende stasionêre fase blyk dus 'n meer belowende benadering op die verlaging van etanol opbrengs en her-kanaliseering weg van etanol produksie. Hierdie benadering met die fokus op groeifase spesifieke oor-uitdrukking dui op 'n unieke strategie vir die verlaging van etanol opbrengs sonder om die redoks balans te beinvloed. / The NRF, IWBT and Stellenbosch University for funding

Para se verificar o efeito de drogas hipolipemizantes sobre a qualidade do ovo, desempenho das aves, níveis de Iípides plasmáticos e colesterol na gema do ovo, foram realizados dois experimentos utilizando-se galinhas poedeiras Shaver. No experimento 1, 240 aves com 30 semanas de idade, foram alimentadas durante 12 semanas com dieta comercial (CON1) acrescida de Probucol a 0,1% (PROB), Gemfibrozil a 0,025% (GEMF) e Lovastatina em três concentrações: 0,0005% (LOV1), 0,001% (LOV2) e 0,0015% (LOV3), totalizando seis tratamentos. No experimento 2, 128 aves com 26 semanas de idade, receberam como alimentação, durante seis semanas, dieta formulada sem ingredientes de origem animal (CON2), acrescida de Colestiramina a 0,2% (COL 1) e 0,3% (COL2) e Lovastatina a 0,005% (LOV4), perfazendo um total de quatro tratamentos. Em ambos os experimentos, a adição das drogas não prejudicou a qualidade da casca e do albúmen dos ovos e, de um modo geral, não determinou efeitos indesejáveis sobre o desempenho produtivo das aves, com exceção da redução observada no peso médio dos ovos no experimento 2. No experimento 1, em relação aos lípides plasmáticos, a adição de drogas à ração determinou reduções de significado estatístico (p<0,05), nos triglicérides, apenas no LOV2 (38,5%), e no colesterol total, nos grupos LOV2 (36,0%), LOV3 (36,8%), PROB (29,6%) e GEMF (30,4%). Não foram consignadas alterações significativas nos níveis de HDL-colesterol em relação ao CON 1, observando-se, com exceção do GEMF, tendência a elevação de seus valores com o uso das diferentes drogas. Verificou-se redução significativa (p<0,05) do colesterol na gema (mg/g) nos grupos LOV1 (7,4%) e LOV3 (12,1%). No experimento 2, os lípides plasmáticos não sofreram alterações de significado estatístico em relação ao CON2, sendo que os triglicérides e o colesterol total mostraram tendência a diminuição no LOV4. A concentração de colesterol na gema (mg/g) permaneceu inalterada, em cotejo com o CON2, mediante a adição das drogas utilizadas no experimento 2. Os efeitos da Lovastatina sobre as concentrações de Iípides sanguíneos e de colesterol do ovo foram menos evidentes no experimento 2, onde as aves apresentavam níveis de Iípides plasmáticos mais reduzidos. Os coeficientes de correlação e as equações de regressão calculados mostraram que o peso da gema aumenta conforme o peso do ovo se eleva (p<0,05), e que um aumento do peso da gema corresponde a um incremento de seu teor de colesterol, indicando que as variações dos níveis de colesterol por gema podem ser, em parte, justificadas pelas diferenças entre os pesos dos ovos. / Two experiments were carried out to evaluate the effect of lipid¬lowering agents upon egg quality, reproductive performance, plasma lipids and egg yolk cholesterol levels of Shaver laying hens. In the first trial, two hundred and forty 30-week-old hens were fed basal diet (commercial ration - CON1) supplemented with 0.1 % Probucol (PROB), 0.025% Gemfibrozil (GEMF), or Lovastatin at 0.0005% (LOV1), 0.001 % (LOV2) and 0.015% (LOV3) for a 12-week experimental period. In experiment 2, one hundred and twenty-eight 26-week-old hens were fed basal diet without animal products (CON2) containing either 0.2% Cholestyramine (CaL 1), 0.3% Cholestyramine (COL2) or 0.005% Lovastatin (LOV4) for a period of six weeks. At the termination of both experiments, it was observed that the supplement of the drugs did not impair albumen and shell quality. In addition, hen performance was not adversely affected, with the exception of the significant reduction (p<0.05) in egg weights observed in experiment 2. In experiment 1, with regard to the plasma lipids, the depression in triglyceride concentrations approached statistical significance (p<0.05) only in LOV2 (38.5%), and total cholesterol was significantly depressed (p<0.05) in LOV2 (36.0%), LOV3 (36.8%), PROB (29.6%) and GEMF (30.4%) groups. HOL-cholesterol levels were not significantly altered by drug treatments; but with the exception of GEMF, there was a trend towards the elevation by the use of other drugs. Egg cholesterol content, expressed per gram of yolk was significantly lowered (p<0.05) in LOV1 (7.4%) and LOV3 (12.1 %). In experiment 2, no significant changes were observed on plasma lipids due to the addition of the drugs, but cholesterol and triglyceride levels tend to reduction in LOV4 group. Egg yolk cholesterol remained unchanged in experiment 2 with the supplement of the drugs. The effect of Lovastatin on plasma lipid and egg yolk cholesterol concentration was less remarkable in experiment 2, when hens presented lower plasma lipid levels. When correlation coefficients and regression equations were calculated, it was found that yolk weight increased linearly (p<0.05) as egg weight raised, and the higher the yolk weight, the higher the yolk cholesterol content, indicating that yolk cholesterol content changes may be partially explained by differences among egg weights.

No presente estudo foram avaliados o perfil lipídico, inflamatório e expressão gênica antes e após cada fase de tratamento de indivíduos hipercolesterolêmicos (HC) com (n=47) e sem (n=37) DM2, e 36 normolipidêmicos (NL). No grupo DM2, foi avaliado o perfil glicêmico. O grupo HC foi orientado a fazer dieta e a não utilizar hipolipemiantes por 4 semanas (fase basal, B), a seguir, tratados com ezetimiba (E: 10mg/d/4sem), sinvastatina (S: 10mg/d/8sem) e sinvastatina e ezetimiba (SE: 10mg cada/d/4sem). O grupo DM2 foi tratado com S (10 ou 20mg/d/4sem) e SE. No plasma foi quantificado, TNF-&#945;, IL1&#946;, IL-6, IL-8, MMP9, MCP1, sICAM1, sVCAM1, e-selectina, leptina, PAI-1, resistina e adiponectina e PCRus. A expressão de mRNA de TNFA, MMP9, MCP1, IL6, IL1B, ICAM1, VCAM1, PAI1, LEP, RETN, ADIPOR1 e ADIPOR2 foi quantificada em células mononucleares por PCR em tempo real. No grupo HC, o colesterol total, LDL-c e apoB foram reduzidos em todas as fases, em comparação com o B (p<0,05). No grupo DM2, o tratamento com SE reduziu o colesterol total, LDL-c e apoB em comparação com S (p<0,05), o perfil glicêmico não foi alterado. No grupo HC, SE reduziu a concentração plasmática de adiponectina quando comparado com as outras fases (p<0,001). A expressão de IL6 foi maior no grupo HC que no grupo NL, e, ao contrário, a expressão de IL1B foi maior no grupo NL (p<0,05). A expressão de IL6 foi maior no tratamento S do grupo com maior resposta de LDL-c (tercil T3>50%, p=0,044) em comparação com o grupo com menor resposta (tercil T1<42%). No grupo DM2, PCRus, sICAM-1 e e-selectina foram reduzidos e sVCAM-1 aumentado, pelo tratamento SE (p<0,05). A expressão de MMP9 foi diminuída na fase SE (p<0,05). PAI1, ICAM1, RETN e ADIPOR1 tiveram maior, e IL6 menor, expressão no grupo que utilizou 20mg que no grupo de 10mg de sinvastatina (p<0,05). Observou-se também que o grupo com maior resposta (T3: redução de LDL-c>30%) teve menor expressão de LEP e ADIPOR1 na fase S, comparado com o grupo com menor resposta (T1: redução de LDL-c<20%) (p<0,05). A expressão de PAI1, VCAM1, RETN LEP, ADIPOR1 e ADIPOR2 foi maior nas fases S e SE, no grupo DM2 que no grupo HC (p<0,05). Em conclusão, a expressão de IL6 é maior em dislipidêmicos, e de IL1B maior em normolipidêmicos. A sinvastatina reduz a expressão de IL6 e a concentração de adiponectina em dislipidêmicos. Em diabéticos, a ezetimiba reduz a concentração de PCRus, sICAM-1 e e-selectina, e a expressão de MMP9, ADIPOR1 e LEP. Diabéticos tem maior expressão de PAI1, VCAM1, RETN, LEP, ADIPOR1 e ADIPOR2 que dislipidêmicos. / We evaluated lipid, inflammatory profiles, and gene expression before and after each treatment of hypercholesterolemic subjects (HC) with (n=47) and without (n=37) T2DM and 36 normolipidemics (NL). The glycemic profile was evaluated in T2DM group. The HC group had a low fat diet, without lowering-cholesterol drugs during four weeks (baseline). Afterwards, this group was treated with ezetimibe (E: 10mg/day/4weeks), sinvastatin (S: 10 mg/day/8weeks), and combined E and S (SE: 10mg each/day/4weeks). The T2DM group was treated with S (10 or 20mg/day/4weeks) and SE. Plasma levels of TNF-&#945;, IL1&#946;, IL-6, IL-8, MMP9, MCP1, sICAM1, sVCAM1, e-selectin, leptin, PAI-1, resistin and adiponectin and hsCRP were measured. TNFA, MMP9, MCP1, IL6, IL1B, ICAM1, VCAM1, PAI1, LEP, RETN, ADIPOR1 e ADIPOR2 mRNA expression in mononuclear cells were quantified by real time PCR. In the HC group, total cholesterol, LDL-C and apoB were reduced in all stages, compared with baseline (p<0.05). In T2DM group, SE treatment reduced total cholesterol, LDL-C and apoB compared with S (p<0.05), glycemic profile was not changed. In HC group, SE reduced plasma adiponectin compared to the other phases (p<0.001). IL6 expression was higher in HC group, and instead, IL1B expression was higher in NL group (p<0.05). IL6 expression was higher in S with higher LDL-c lowering group (tertile T3>50%, p = 0.044) compared with the lower LDL-c lowering group (tertile T1<42%). In the group DM2, hsCRP, sICAM and e-selectin were reduced and sVCAM increased by treatment SE (p<0.05). MMP9 expression was reduced in the SE (p<0.05). PAI1, ICAM1, RETN, ADIPOR1 and ADIPOR2 had higher, and IL6 lower, expression in the 20mg simvastatin group than 10mg group (p <0.05). It was also observed that the higher LDL-c lowering group (T3: reduction of LDL-C>30%) had lower LEP and ADIPOR1 expression in S phase, compared with the lower LDL-c lowering group (T1: reduction of LDL-C<20%) (p <0.05). PAI1, VCAM1, RETN LEP, ADIPOR1 and ADIPOR2 expression was higher in S and SE in T2DM group than in the HC group (p<0.05). In conclusion, IL6 expression is increased and IL1B decreased in dyslipidemia. Simvastatin reduces IL6 expression and adiponectin levels in dyslipidemic. In T2DM, ezetimibe reduces hsCRP, sICAM-1 and E-selectin levels and MMP9, ADIPOR1 and LEP expression. T2DM have higher PAI1, VCAM1, RETN, LEP, ADIPOR1 and ADIPOR2 expression of than dyslipidemics.